All Articles

Officials with the FDA have approved inavolisib (Itovebi, Genentech, Inc.) with palbociclib (Ibrance) and fulvestrant (Faslodex) for adults with endocrine-resistant,... Read More ›

Officials with the FDA have approved nivolumab (Opdivo, Bristol Myers Squibb Company) with platinum-doublet chemotherapy as neoadjuvant treatment,... Read More ›

Selpercatinib (Retevmo, Eli Lilly and Company) is now available for adult and pediatric patients 2 years of age and older with advanced or metastatic medullary thyroid cancer with a RET mutation,... Read More ›

Osimertinib (Tagrisso, AstraZeneca Pharmaceuticals) has received another new indication,... Read More ›

Officials with the FDA have approved isatuximab-irfc (Sarclisa, Sanofi-Aventis U.S. LLC) with bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone for adults... Read More ›

Amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.) with carboplatin and pemetrexed has been green-lighted by the FDA for adult patients... Read More ›

On September 17, 2024, FDA officials approved pembrolizumab (Keytruda, Merck)... Read More ›

This publication provides ongoing lists of US-based trials that are actively recruiting. This issue is focused on pancreatic cancer because November is Pancreatic Cancer Awareness Month. Read More ›

Patient care is very personal. The physicians and care teams of cancer practices constantly assess what they see and hear relating to the patients when they are in the office. Unfortunately, patients are outside the office more than they are in front of the care team. Read More ›

Coordinating technology and virtual care enables modalities to address both behavioral health and social issues and simultaneously close gaps in care. Read More ›